SUVEN

Study Title: SUVEN-502 Study

Purpose

Individuals with Alzheimer's Disease are invited to participate in SUVEN-502 to determine the effectiveness of oral masupirdine, a medication targeting the serotonin system, and its ability to treat agitation associated with dementia of the Alzheimer's type compared to oral placebo. The study is 20 weeks long. In total, there will be 7 visits. Subjects will receive psychosocial support, undergo medical history, questionnaires/interviews related to agitation symptoms, cognitive assessments in addition to taking the oral medication and medication monitoring. Subjects will also need a study partner to participate in the study with them throughout the entire study.

(Principal Investigator: Pauline Wu, DO, Easton Center’s Katherine and Benjamin Kagan Alzheimer’s Disease Treatment Development Program)

Contact: Lorena Macias at (310) 794-6191 or send an email to LorenaMacias@mednet.ucla.edu to participate in this study or for more information.

More information on the SUVEN study is available at clinicaltrials.gov ID#: NCT05397639.